Investigators will present detailed findings from a phase 2 study assessing a tambiciclib-based regimen in patients with relapsed/refractory AML at ASH 2026.
News|Videos|July 4, 2017
Updates in the Treatment of Secondary Acute Myeloid Leukemia
Author(s)Bruno C. Medeiros, MD
This video reviews the biology of secondary acute myeloid leukemia and highlights some of the latest findings in the treatment of this disease.
Advertisement
In this video, Bruno C. Medeiros, MD, of the Stanford School of Medicine in California, reviews the biology of secondary acute myeloid leukemia and highlights some of the latest findings in the treatment of this disease, including the promising novel agent CPX-351.
Medeiros spoke on this topic during an education session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held last month in Chicago.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves OncoMate MSI Dx as Pembrolizumab Companion Diagnostic in MSI-H Solid Tumors
2
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumors
3
Hyperthermic Mitomycin C Yields 68% 1-Year HG-RFS in BCG-Unresponsive NMIBC
4
European Commission Expands Melflufen Label to Third-Line Multiple Myeloma
5